flibanserin ADDYI

Class: Norepinephrine-Dopamine Disinhibitor
FDA Indications: Hypoactive Sexual Desire Disorder
Off-Label Use:
Prescribing
Forms: 100mg tablet
Dose Range: 100 mg/day
Starting: 100 mg taken once daily at bedtime. Discontinue treatment after 8 weeks if no improvement.

NAMI drug fact sheet

Precautions
Contraindications: Concomitant alcohol use; hepatic impairment
Serious Side Effects: Severe hypotension and syncope with concomitant alcohol use
Side Effects: sedation/somnolence, dizziness, xerostomia, nausea, insomnia, fatigue, transaminitis
Pharmacodynamics
1° MOA: Postsynaptic 5-HT1A agonist/5-HT2A antagonist
Target: Agonist at Postsynaptic 5HT1A, antagonist at 5HT2A, moderate partial agonist at D4, 5HT2B, & 5HT2C
Pharmacokinetics
t½: 11° TMAX: 2-4°
Substrate of: 3A4; 2C19
Inhibits: ∅ ; Induces:
Active Metabolites:
DDIs
Misc
  • - preferentially activates 5-HT1A in the prefrontal cortex increasing downstream DA and NE levels; its 5HT2C antagonism also enhances mesocorticolimbic DA function
  • - was developed as an antidepressant, but failed to show efficacy
  • - dosed QHS because administration during waking hours ↑ risk of hypotension, syncope, accidental injury, and central nervous system depression
Special Populations

Category Not assigned.—Safety has not been established during pregnancy; data from animal studies cannot rule out the potential for fetal harm

Not recommended


Not indicated for use in geriatric patients


AUC ↑'d 1.1-fold in patients with mild to moderate renal impairment and 1.2-fold in patients with severe renal impairment

Contraindicated for use in patients with any degree of hepatic impairment

logo

Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated April 20 2018 09:28:33. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.